▸ International trade disputes, including United States trade tariffs and retaliatory tariffs, could adversely impact our business.· · · · ● 1 ▸ We may fail to recover our accounts receivable in a timely manner, which may affect our financial condition and results of operations.· · · · ● 1 ▸ As described above, in June 2024, our stockholders voted to approve an amendment to our Charter to add a provision with respect to the automatic conversion of our Class B common stock effective as of December 22, 2028.· · · ● ● 2 ▸ Future sales of substantial amounts of our Class A common stock, or the possibility that such sales could occur, could adversely affect the market price of our Class A common stock.· · · ● ● 2 ▸ We may be required to obtain a new 510(k) clearance or a PMA for significant post-market modifications to our products, including any modifications made to our commercially marketed devices.· · ● ● ● 3 rw ▸ Changes in laws or regulations, or a failure to comply with any laws and regulations, or any litigation that we may be subject to or involved in may adversely affect our business, investments and results of operations.· ● ● ● ● 4 ▸ We could fail to maintain the listing of our Class A common stock on Nasdaq, which could seriously harm the liquidity of our shares and our ability to raise capital or complete a strategic transaction.· ● ● ● ● 4 ▸ We have undertaken internal restructuring activities in the past that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition.· ● ● ● ● 4 rw ▸ We maintain our cash at financial institutions, often in balances that exceed federally insured limits.· ● ● ● ● 4 ▸ SEC regulations limit the funds we can raise during 12 months under our shelf registration statement on Form S-3.· · ● · · 1 ▸ While we strive to comply with the GDPR and its UK and Swiss equivalents, as applicable, there can be no assurance that as our operations evolve, our efforts to comply or to remain in compliance will be fully successful.· · ● · · 1 ▸ It is unclear at this time whether and how various activities initiated or announced by the FDA to modernize the U.S. medical device· ● · · · 1 ▸ group Difficulties in staffing and managing our international operations;● ● ● · · 3 ▸ Limits on our ability to penetrate international markets if we are required to manufacture our products locally;● ● ● · · 3 ▸ Natural disasters and economic instability, including outbreak of disease, boycotts, curtailment of trade and other market restrictions;● ● ● · · 3 ▸ Regulatory and compliance risks that relate to maintaining accurate information and control over activities subject to regulation under the U.S. Foreign Corrupt Practices Act, and comparable laws and regulations in other countries.● ● ● · · 3 ▸ The Charter does not limit the ability of the Sponsor to compete with the Company.● · · · · 1 ▸ We may need to raise additional capital to fund commercialization plans for our products, including manufacturing, sales and marketing activities, expand our investments in research and development, and commercialize new products and applications.● ● · · · 2 ▸ Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.● ● ● ● ● 5 ▸ Any of these factors could significantly harm our future international expansion and operations and, consequently, have a material adverse effect on our business, financial condition and results of operations.● ● ● ● ● 5 ▸ As international expansion of our business occurs, it will expose us to market, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.● ● ● ● ● 5 ▸ Because we are a “controlled company” within the meaning of the Nasdaq listing rules, our stockholders may not have certain corporate governance protections that are available to stockholders of companies that are not controlled companies.● ● ● ● ● 5 ▸ Delaware law and provisions in our Charter and bylaws could make a takeover proposal more difficult.● ● ● ● ● 5 ▸ Digital marketing and social media efforts may expose us to additional regulatory scrutiny, including from the Federal Trade Commission (the “FTC”) and other consumer protection agencies and regulators.● ● ● ● ● 5 ▸ Health technology development is costly and involves continual technological change, which may render our current or future products obsolete.● ● ● ● ● 5 rw ▸ If we are found to have violated laws protecting the confidentiality of health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business.● ● ● ● ● 5 ▸ If we are unable to attract, recruit, train, retain, motivate and integrate key personnel and expand our organization, our operations may be disrupted and we may not achieve our goals.● ● ● ● ● 5 rw ▸ If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.● ● ● ● ● 5 ▸ If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.● ● ● ● ● 5 ▸ If we dedicate significant resources to our international operations and are unable to manage these risks effectively, our business, operating results and financial condition may be adversely affected.● ● ● ● ● 5 ▸ If we do not successfully optimize and operate our sales and potential future distribution channels or we do not effectively expand and update our infrastructure, our operating results and customer experience may be negatively impacted.● ● ● ● ● 5 ▸ If we fail to meet any applicable product quality standards and our products are the subject of recalls or safety alerts, our reputation could be damaged, we could lose customers, and our revenue and results of operations could decline.● ● ● ● ● 5 ▸ If we fail to obtain regulatory authorizations in other countries for existing products or products under development, we will not be able to commercialize these products in those countries.● ● ● ● ● 5 ▸ In the future, we may rely on licenses from third parties, and if we lose such licenses, then we may be subjected to future litigation.● ● ● ● ● 5 rw ▸ Intellectual property rights do not necessarily address all potential threats.● ● ● ● ● 5 ▸ Issued patents covering our products could be found invalid or unenforceable if challenged.● ● ● ● ● 5 ▸ Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.● ● ● ● ● 5 ▸ Our employees, independent contractors, consultants, manufacturers and suppliers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.● ● ● ● ● 5 ▸ Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.● ● ● ● ● 5 ▸ Our success depends upon market acceptance of our products and services, our ability to develop and commercialize existing and new products and services and generate revenues, and our ability to identify new markets for our technology.● ● ● ● ● 5 ▸ Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.● ● ● ● ● 5 ▸ Potential conflicts of interest may arise among the holders of our Class B common stock and the holders of our Class A common stock.● ● ● ● ● 5 ▸ Quality problems could lead to recalls or safety alerts and/or reputational harm and could have a material adverse effect on our business, results of operations, financial condition and cash flows.● ● ● ● ● 5 ▸ Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our Class A common stock.● ● ● ● ● 5 ▸ group Risks Related to Healthcare Industry Shifts and Changing Regulations● ● ● ● ● 5 ▸ group Risks Related to Our Businesses● ● ● ● ● 5 ▸ group Risks Related to Our Financial Condition and Capital Requirements● ● ● ● ● 5 ▸ group Risks Related to Our Securities and to Being a Public Company● ● ● ● ● 5 ▸ group Risks Related to our Intellectual Property● ● ● ● ● 5 ▸ Should any of these events occur, they could materially adversely affect our business, financial condition, results of operations and prospects.● ● ● ● ● 5 ▸ The U.S. law relating to the patentability of certain inventions in the life sciences and medical technology industry is uncertain and rapidly changing, which may adversely impact our existing patents or our ability to obtain patents in the future.● ● ● ● ● 5 ▸ The grant of registration rights pursuant to the Registration Rights Agreement, the PIPE Subscription Agreements and the Letter Agreement, and the future exercise of such rights, may adversely affect the market price of our Class A common stock.● ● ● ● ● 5 ▸ The obligations associated with being a public company involve significant expenses and require significant resources and management attention, which may divert from our business operations.● ● ● ● ● 5 rw ▸ The occurrence of any of these events may have a material adverse effect on our business, financial condition and results of operations.● ● ● ● ● 5 ▸ There is no guarantee that the FDA will grant 510(k) clearance or premarket approval of our future products, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.● ● ● ● ● 5 rw ▸ U.S. taxation of international business activities or the adoption of tax reform policies could materially impact our future financial position and results of operations.● ● ● ● ● 5 ▸ Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.● ● ● ● ● 5 ▸ We are an early-stage health technology company with a history of net losses, which we expect to continue, and we may not be able to generate meaningful revenues or achieve and sustain profitability in the future.● ● ● ● ● 5 rw ▸ We are subject to export and import control laws and regulations that could impair our ability to compete in international markets or subject us to liability if we violate such laws and regulations.● ● ● ● ● 5 ▸ We are subject to extensive government regulation, which could restrict the development, marketing, sale and distribution of our products and could cause us to incur significant costs.● ● ● ● ● 5 ▸ We do not intend to pay cash dividends for the foreseeable future.● ● ● ● ● 5 ▸ We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.● ● ● ● ● 5 ▸ We have experienced and may continue to experience pricing pressures from contract suppliers or manufacturers on which we rely.● ● ● ● ● 5 rw ▸ We have limited experience in marketing and selling our products and related services, and if we are unable to successfully commercialize our products and related services, our business and operating results will be adversely affected.● ● ● ● ● 5 ▸ We may be subject to claims challenging the inventorship and ownership of our patents and other intellectual property.● ● ● ● ● 5 ▸ We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their other clients or former employers, which could subject us to costly litigation.● ● ● ● ● 5 ▸ We may be subject to enforcement action if we engage in improper or off-label marketing or promotion of our commercial medical device products, including fines, penalties and injunctions.● ● ● ● ● 5 ▸ We may face exposure to foreign currency exchange rate fluctuations.● ● ● ● ● 5 ▸ We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position.● ● ● ● ● 5 rw ▸ We may not be able to protect our intellectual property rights throughout the world.● ● ● ● ● 5 ▸ We will be dependent upon the success of our sales and customer acquisition and retention strategies.● ● ● ● ● 5 
